PubMed Health⌕ Search

Biomedical subjects

R N Millar

Publications and source records attributed to R N Millar.

At least 19 recordsLinked to original sources

Supraventricular tachycardia during spinal anaesthesia for caesarean section.

A woman of 40 weeks' gestation, who was apparently previously healthy, required emergency caesarean section after a failed vacuum delivery. While under spinal anaesthesia she developed a supraventricular tachycardia of unknown origin. Intravenous verapamil resulted in a conversion to sinus rhythm. Further investigations confirmed Wolff-Parkinson-White syndrome, for which she required ablation therapy. Appropriate methods of cardioversion in this clinical setting are discussed.

Journal Article↗

1998 survey of cardiac pacing in South Africa--report of the working group on registries of the cardiac arrhythmia society of South Africa (CASSA).

BACKGROUND: Permanent pacemakers provide effective relief of symptoms and are life-saving in patients with symptomatic heart block. Since pacemakers are only implanted by cardiologists or cardiothoracic surgeons in tertiary hospitals, the rates of pacemaker implantation provide a readily auditable measure of tertiary health care. METHODS: A survey was conducted of pacemaker implantation in South Africa in 1998, using questionnaires completed by implanters and information on the total number of pacemakers sold during the period, supplied by pacemaker distributors. RESULTS: A total of 1,643 new pacemakers were implanted in 1998 by 112 doctors working in 31 institutions (9 public and 22 private). The annual implant rate per million population was 39, compared with 31/million in 1995, an increase of 25.8%. Public hospitals accounted for 31.7% of primary pacemaker implants in 1998 as opposed to 37% in 1995. Practice in the public sector differed from that in the private sector in that atrioventricular (AV) block was the major indication for pacing in 75.3% versus 45.3%, whereas sinus node dysfunction accounted for 34.9% of private patients, as opposed to 16.2% of public hospital patients. Simple VVI single-chamber pacemakers accounted for 49.5% of public hospital implants versus only 9.6% in private patients. The reverse was true for dual-chamber implants (12.1% v. 42.3%). Severe cost constraints in the public sector have resulted in increasing use of cheaper single-chamber pacemakers for more stringent indications (predominantly AV block). The overall implant rate remains low compared with a median of 283/million in Europe. Large discrepancies persist between race groups (232/million whites, as opposed to 8.8/million blacks) and regions (89.3/million in the Western Cape versus 10.8/million in the four provinces without pacemaker implanters). CONCLUSION: It is likely that socio-economic factors play a major role in the unequal distribution of this highly effective treatment for potentially lethal bradyarrhythmias. The changing trends in pacemaker implantations indicate a shift of tertiary health care resources from the public to the private sectors.

Data Collection↗

Long-term survival after permanent pacemaker implantation in young adults: 30 year experience.

The goal of the present study was to determine the etiology of conduction disease and long-term outcome for young adults who undergo permanent pacemaker implantation. Permanent pacing was performed in 232 patients aged 21-50 years, 135 males and 97 females, from 1965 through 1995. One hundred and twenty-six subjects (54%) had evidence of structural heart disease, while idiopathic conduction disease accounted for 46%. About half (54%) of 106 patients with structural heart disease had surgically induced heart block. Pacing mode at primary implantation was single chamber in 65% and dual chamber in 35%. Follow-up ranged from 12-387 months, with a mean of 104-months. At the last follow-up, 133 of 232 patients (57%) were alive, 40 (17%) had died, 30 (13%) were lost to follow-up, 26 (11%) were transferred elsewhere, and 3 (1%) explanted. Patients with sick sinus syndrome had similar outcomes to those with AV block. There was a sharp decline in survival during the first six months; 7.5% of the sample died within the first year following their first pacemaker operation. After the first year, the decline in survival slowed and 70% of the patients could be expected to survive beyond 20 years. The overall survival of young patients without structural heart disease who received a permanent pacemaker was comparable to an age- and sex-matched control population, while patients with structural heart disease performed significantly worse than the control population.

Adult↗

VDD pacing in persistent left superior vena cava.

Although persistent left superior vena cava (PLSVC) is the most common major venous anomaly of the heart, associated absence of the right superior vena cava with normal visceral situs is exceedingly rare. Such a patient presented with complete heart block requiring permanent pacing. This was achieved successful using a single lead VDD system via the PLSVC with atrial sensing in the coronary sinus.

Cardiac Pacing, Artificial↗

The haemodynamic correlations of the cardiopulmonary flow index, a relatively non-invasive technique for diagnosis of myocardial pump insufficiency.

The cardiopulmonary flow index (CPFI) is the ratio of cardiopulmonary blood volume to stroke volume. OBJECTIVE. To compare the CPFI derived from a first-pass radiocardiogram and electrocardiogram with the usual haemodynamic measurements obtained by bedside catheterisation. DESIGN. Sixty-one patients in a coronary care unit who had flow-directed pulmonary artery catheterisation for clinical indications had a CPFI recorded together with the usual haemodynamic measurements and calculations. RESULTS. In patients with myocardial pump failure without significant pulmonary disease, linear regression analysis indicated that the best fit for the CPFI could be obtained with a model that used the inverse of stroke index and pulmonary capillary wedge pressure as independent variables. Ninety-six per cent of the variation in CPFI can be explained by variations in pulmonary capillary wedge pressure and stroke index. The CPFI correlated less well with these variables in patients with concomitant lung disease. CONCLUSION. The CPFI is a potentially useful and relatively non-invasive index of haemodynamic function in acutely ill patients without significant pulmonary disease.

Blood Volume↗

Pacemaker induced superior vena cava obstruction: management by spiral vein graft.

A 35-year-old male developed superior vena cava (SVC) obstruction due to multiple retained pacemaker leads. This caused cyanosis and suffusion of the head and neck during arm exercise, with desaturation from 99%-90% demonstrated by ear oximetry. The SVC was bypassed using a spiral vein graft because of worsening symptoms. Dramatic improvement resulted, with desaturation no longer demonstrable.

Adult↗

A prospective study of electrical cardioversion for sustained tachycardias by emergency unit personnel.

Acute symptomatic tachyarrhythmias are commonly seen by emergency unit personnel. Electrical cardioversion is often used at Groote Schuur Hospital to treat such patients because of concerns about the safety and efficacy of intravenous anti-arrhythmic agents. All patients presenting with acute symptomatic tachyarrhythmias who were managed only by the staff of the Emergency Unit were entered into the study to assess the efficacy and safety of direct current (DC) cardioversion. Those with sinus tachycardia or atrial fibrillation of more than 24 hours' duration were excluded. Staff, on joining the unit, were instructed in the use and technique of DC cardioversion, and given simple guidelines for the management of acute tachyarrhythmias. Fifty-three patient events were seen over a period of 16 months: 7 patients had ventricular tachycardia, 21 had atrial flutter, 20 had paroxysmal junctional re-entry tachycardia, 4 had atrial fibrillation and 1 had multifocal atrial tachycardia. Fifty-two were successfully converted to sinus rhythm. One patient with atrial flutter and 9 with paroxysmal junctional re-entry tachycardia reverted after undergoing vagal manoeuvres or receiving intravenous verapamil. Of the remaining 43 patients, 42 (98%) were cardioverted with synchronised DC shock under midazolam sedation (7/7 ventricular tachycardia, 20/20 atrial flutter, 11/11 paroxysmal junctional re-entry tachycardia, 4/4 atrial fibrillation, 0/1 multifocal atrial tachycardia). Four patients had their sedation electively reversed with flumazenil. No complications occurred. DC cardioversion was only considered inappropriate in the 1 patient with multifocal atrial tachycardia. This study shows that if simple guidelines are followed, non-cardiologist junior medical personnel can safely and effectively manage sustained, acute, symptomatic tachyarrhythmias by employing DC cardioversion as and when appropriate.

Atrial Fibrillation↗

Cardiovascular collapse due to intravenous verapamil in two patients with persistent atrial tachycardia.

Intravenous verapamil was given to two haemodynamically stable patients with persistent atrial tachycardia, resulting in circulatory arrest requiring CPR in one and collapse with unrecordable blood pressure in the other. Both responded to resuscitation and tachycardia was subsequently controlled with propranolol in one and sotalol in the other. Factors contributing to the cardiovascular collapse included: (i) left ventricular dysfunction; and (ii) failure to convert the tachycardia to sinus rhythm. It was concluded that verapamil may be dangerous in supraventricular tachycardia not due to atrioventricular (AV) junctional re-entry, despite normal blood pressure and perfusion, particularly if left ventricular dysfunction were present. If the diagnosis of AV junctional re-entry is in doubt, adenosine is preferable as it is less likely to cause haemodynamic collapse and will assist in making the diagnosis.

Adult↗

Normal left ventricular function does not protect against propafenone-induced incessant ventricular tachycardia.

Propafenone is a class Ic anti-arrhythmic agent with mild beta-blocking properties which has recently become available in South Africa. We have used the drug in 3 patients with sustained monomorphic ventricular tachycardia not due to ischaemic heart disease. All had normal left ventricular function; 1 had Wegener's granulomatosis and 2 had arrhythmogenic right ventricular dysplasia. In the latter 2, propafenone provoked incessant monomorphic ventricular tachycardia which persisted for more than 24 hours despite repeated efforts at termination. The morphology was similar to the patients' spontaneous ventricular tachycardia, but the rate was slower and the QRS complexes broader, consistent with propafenone's marked ability to slow intraventricular conduction. It is postulated that incessant tachycardia results from perpetuation of re-entry due to marked conduction slowing produced by the drug. Previous reports have suggested that this is most likely to occur in patients with poor left ventricular function, but our experience indicates that those with normal left ventricular function are also at risk, particularly if the substrate for re-entry is present. Propafenone, like all other powerful anti-arrhythmic agents, may provoke life-threatening arrhythmias and should be used with great caution after due consideration of the indications, even in patients with normal left ventricular function.

Adult↗

Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.

One hundred thirty-one patients presenting with acute myocardial infarction (AMI) a mean of 3 hours after the onset of symptoms were treated with oral aspirin and intravenous thrombolytic therapy followed by heparin. One hundred eleven patients (85%) also received intravenous followed by oral beta blockers. Twenty-one patients (19%) discontinued the beta blocker because of complications. Five (4.5%) required the addition of diuretic drugs or converting enzyme inhibitors. Six patients (5%) discontinued the beta blocker after complete mechanical revascularization, and 1 patient was noncompliant. Long-term treatment continued in 90 patients (69%) over a 2-year follow-up period (average 13 months). There were 3 infarct extensions and 3 reinfarctions (5%). Overall mortality at 2 years was 10%. Intravenous beta blockers are well tolerated in most patients treated with thrombolytic agents, aspirin and heparin. They may further improve the survival benefit of chronic beta blocker therapy in the period after AMI.

Administration, Oral↗

Surgery for the Wolff-Parkinson-White syndrome. The Groote Schuur Hospital experience.

Surgical division of accessory atrioventricular (AV) connections has been performed on 9 patients with the Wolff-Parkinson-White (WPW) syndrome at Groote Schuur Hospital. All patients had symptomatic paroxysmal tachycardia. The indication for surgery in 5 patients was poor control on antiarrhythmic drugs. Surgery was performed on a 15-year-old boy to prevent lifelong dependence on drugs, although his atrial fibrillation (ventricular rate greater than 300/min) was controllable with sotalol 1,280 mg daily. The remaining 3 patients required cardiac surgery for other indications and therefore their accessory pathways (APs) were divided concurrently. The AP was localised by pre-operative endocardial mapping and intra-operative epicardial mapping. There were 4 posteroseptal, 3 left free-wall and 2 right free-wall pathways. An endocardial approach was used to divide the pathways. All 5 free-wall APs were successfully divided without complications or recurrence. However, 1 patient with paroxysmal atrial fibrillation and severe unstable angina due to coronary artery disease died unexpectedly 10 days after 4-vessel coronary bypass grafting and division of a posteroseptal AP. Postoperative complications occurred in a further 2 patients with posteroseptal APs. One patient developed complete heart block and is now asymptomatic with a DDD pacemaker, while the other had recurrence of retrograde bypass conduction postoperatively, but is now successfully controlled on sotalol. Therefore 7 of the 8 survivors are free of recurrence of tachycardia on no anti-arrhythmic drugs after a mean follow-up of 14.3 months. New insights into the surgical technique, particularly for division of posteroseptal pathways, can be expected to improve the outlook.

Adolescent↗

Efficacy of oral sotalol in reentrant ventricular tachycardia.

Oral sotalol was given to 64 patients (78% postinfarction) with recurrent, reentrant ventricular tachycardia (VT) during an average follow-up period of 19.7 months. Fifty-nine (92%) patients had previously experienced recurrent ventricular tachycardia, in spite of having received an average of three conventional antiarrhythmic drugs (13 had previously failed on other Class III drugs). The nature and mechanism of the VT was proved with electrophysiologic testing (EPS), and the chronic sotalol dosage was determined by repeated EPS at 3- to 4-day intervals until the VT was no longer inducible. Sotalol failed in five patients and was discontinued in six patients because of severe side effects (three proarrhythmic effects, including two with torsades de pointes)--a total of 18%. Sotalol was successful alone in 42 patients (65%) and in combination with another antiarrhythmic drug in 11 patients (18%). The average dose of sotalol required for success was 589 mg; 658 mg was the mean daily dose when given alone and 486 mg when given in combination. Side effects were common and were due mainly to the beta-blocking effects of sotalol. Dual chamber pacing was required by 11 patients because of poorly tolerated bradycardia, and 14 patients remained symptomatic from worsening of the cardiac failure in spite of pacing, increased diuretics, or vasodilator therapy. The average drug dosage was the same for symptomatic (680 mg) and asymptomatic (627 mg) patients. Sotalol is a valuable antiarrhythmic drug for reentrant ventricular tachycardia. High doses are needed, and at these doses the beta-blocking activity is responsible for most of the side effects.

Administration, Oral↗

Efficacy of sotalol in controlling reentrant supraventricular tachycardias.

Sotalol is unique among beta-blocking agents having significant Class III antiarrhythmic action. In a series of 22 patients with Wolff-Parkinson-White (WPW) syndrome and seven patients with atrioventricular nodal reentry tachycardia (AVNRT) resistant to multiple drugs, sotalol was studied by acute electrophysiologic means, as well as by long-term clinical follow-up ranging from 1 to 47 months. Sustained reciprocating tachycardia was rendered noninducible in 13 of 18 patients with WPW and in 5 of 6 with AVNRT. Long-term control of symptomatic tachycardia was achieved in 77% of patients with WPW and in 57% of patients with resistant AVNRT. Side effects were those associated with beta blockade. Two patients developed ventricular irritability associated with excessive QT prolongation.

Adolescent↗